fenofibrate has been researched along with Left Ventricular Hypertrophy in 10 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the effect of PPAR alpha activator fenofibrate on left ventricular hypertrophy and myocardium PPAR alpha (peroxisome proliferator-activated receptor-alpha) expression in spontaneously hypertensive rats (SHR)." | 7.74 | [PPAR alpha activator fenofibrate regressed left ventricular hypertrophy and increased myocardium PPAR alpha expression in spontaneously hypertensive rats]. ( Chen, HJ; Chen, JZ; Wang, XX; Yu, M, 2007) |
| "To investigate the effect of PPAR alpha activator fenofibrate on left ventricular hypertrophy and myocardium PPAR alpha (peroxisome proliferator-activated receptor-alpha) expression in spontaneously hypertensive rats (SHR)." | 3.74 | [PPAR alpha activator fenofibrate regressed left ventricular hypertrophy and increased myocardium PPAR alpha expression in spontaneously hypertensive rats]. ( Chen, HJ; Chen, JZ; Wang, XX; Yu, M, 2007) |
| "Treatment with fenofibrate, a PPARĪ± agonist, normalized both FA and glucose uptake while reducing LV dilation caused by AR." | 1.42 | Transcriptional Changes Associated with Long-Term Left Ventricle Volume Overload in Rats: Impact on Enzymes Related to Myocardial Energy Metabolism. ( Arsenault, M; Couet, J; Dhahri, W; Drolet, MC; Gascon, S; Lachance, D; Lecomte, R; Rousseau, JA; Roussel, E; Sarrhini, O; Walsh-Wilkinson, E, 2015) |
| "Fenofibrate was used as the PPARĪ± agonist." | 1.37 | Reactivation of peroxisome proliferator-activated receptor alpha in spontaneously hypertensive rat: age-associated paradoxical effect on the heart. ( Nair, RR; Purushothaman, S; Sathik, MM, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dhyani, N | 1 |
| Saidullah, B | 1 |
| Fahim, M | 1 |
| Omanwar, S | 1 |
| Roussel, E | 1 |
| Drolet, MC | 1 |
| Walsh-Wilkinson, E | 1 |
| Dhahri, W | 1 |
| Lachance, D | 1 |
| Gascon, S | 1 |
| Sarrhini, O | 1 |
| Rousseau, JA | 1 |
| Lecomte, R | 1 |
| Couet, J | 1 |
| Arsenault, M | 1 |
| Zhang, J | 1 |
| Cheng, Y | 1 |
| Gu, J | 1 |
| Wang, S | 1 |
| Zhou, S | 1 |
| Wang, Y | 1 |
| Tan, Y | 1 |
| Feng, W | 1 |
| Fu, Y | 1 |
| Mellen, N | 1 |
| Cheng, R | 1 |
| Ma, J | 1 |
| Zhang, C | 1 |
| Li, Z | 1 |
| Cai, L | 1 |
| Baraka, A | 1 |
| AbdelGawad, H | 1 |
| Purushothaman, S | 1 |
| Sathik, MM | 1 |
| Nair, RR | 1 |
| Irukayama-Tomobe, Y | 1 |
| Miyauchi, T | 1 |
| Sakai, S | 1 |
| Kasuya, Y | 1 |
| Ogata, T | 1 |
| Takanashi, M | 1 |
| Iemitsu, M | 1 |
| Sudo, T | 1 |
| Goto, K | 1 |
| Yamaguchi, I | 1 |
| Erol, A | 1 |
| Ichihara, S | 1 |
| Obata, K | 1 |
| Yamada, Y | 1 |
| Nagata, K | 1 |
| Noda, A | 1 |
| Ichihara, G | 1 |
| Yamada, A | 1 |
| Kato, T | 1 |
| Izawa, H | 1 |
| Murohara, T | 1 |
| Yokota, M | 1 |
| Lebrasseur, NK | 1 |
| Duhaney, TA | 1 |
| De Silva, DS | 1 |
| Cui, L | 1 |
| Ip, PC | 1 |
| Joseph, L | 1 |
| Sam, F | 1 |
| Chen, HJ | 1 |
| Chen, JZ | 1 |
| Wang, XX | 1 |
| Yu, M | 1 |
10 other studies available for fenofibrate and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Fenofibrate ameliorates neural, mechanical, chemical, and electrical alterations in the murine model of heart failure.
Topics: Animals; Baroreflex; Blood Pressure; Disease Models, Animal; Electrocardiography; Energy Metabolism; | 2019 |
Transcriptional Changes Associated with Long-Term Left Ventricle Volume Overload in Rats: Impact on Enzymes Related to Myocardial Energy Metabolism.
Topics: Animals; Aortic Valve Insufficiency; Cardiac Volume; Disease Models, Animal; Energy Metabolism; Feno | 2015 |
Fenofibrate increases cardiac autophagy via FGF21/SIRT1 and prevents fibrosis and inflammation in the hearts of Type 1 diabetic mice.
Topics: Animals; Autophagy; Blood Glucose; Cell Line; Diabetes Mellitus, Experimental; Diabetes Mellitus, Ty | 2016 |
Targeting apoptosis in the heart of streptozotocin-induced diabetic rats.
Topics: Animals; Apoptosis; Cardiomyopathies; Diabetes Complications; Diabetes Mellitus, Experimental; Fenof | 2010 |
Reactivation of peroxisome proliferator-activated receptor alpha in spontaneously hypertensive rat: age-associated paradoxical effect on the heart.
Topics: Aging; Animals; Azo Compounds; Blood Pressure; Body Weight; Cholesterol; Disease Models, Animal; Ene | 2011 |
Endothelin-1-induced cardiac hypertrophy is inhibited by activation of peroxisome proliferator-activated receptor-alpha partly via blockade of c-Jun NH2-terminal kinase pathway.
Topics: Animals; Animals, Newborn; Aorta; Cells, Cultured; Disease Models, Animal; Endothelin-1; Fenofibrate | 2004 |
PPARalpha activators may play role for the regression of ventricular hypertrophy in hypertensive and hyperlipidemic patients.
Topics: Clinical Trials as Topic; Evidence-Based Medicine; Fenofibrate; Humans; Hyperlipidemias; Hypertensio | 2006 |
Attenuation of cardiac dysfunction by a PPAR-alpha agonist is associated with down-regulation of redox-regulated transcription factors.
Topics: Animals; Cytokines; Down-Regulation; Fenofibrate; Glucose; Heart Ventricles; Hypertension; Hypertrop | 2006 |
Effects of fenofibrate on cardiac remodeling in aldosterone-induced hypertension.
Topics: Aldosterone; Animals; Blood Pressure; Extracellular Matrix; Fenofibrate; Fibrosis; Heart; Heart Rate | 2007 |
[PPAR alpha activator fenofibrate regressed left ventricular hypertrophy and increased myocardium PPAR alpha expression in spontaneously hypertensive rats].
Topics: Animals; Blood Pressure; Blotting, Western; Fenofibrate; Hypertension; Hypertrophy, Left Ventricular | 2007 |